Reporter: Aviva Lev-Ari, PhD, RN
ABOUT CGC
The Consumer Genetics Conference covers the key issues facing clinical genetics, personalized medicine, molecular diagnostics, and consumer-targeted DNA applications. It provides a unique outlet where all voices can be heard: pro & con, physician & consumer, research & clinical, academic & corporate, financial & regulatory. CGC is more than just another personalized medicine conference. Since the inaugural meeting in 2009, CGC has been the place where consumer companies learn genomics, and where genomics companies learn how to approach consumers. This year’s event is highlighted by keynote presentations from:
– Kenneth Chahine, Ph.D., J.D., ancestry.com
– Jay Flatley, President and CEO, Illumina
– Lee Silver, Ph.D., Princeton University
Spanning three days, the conference will focus on:
– Day 1: Technology
– Day 2: Business + Translation
– Day 3: Application
And 40+ Cutting-Edge Presentations on:
– Personal Genomics
– Third-Generation Sequencing
– Molecular Diagnostics
– Investment & Funding Opportunities
– Genome Interpretation
– The Future of Personalized Medicine
– Big Data
– Prenatal/Neonatal & Disease Diagnostics
– Empowering Patients
– Nutrition, Food Genetics & Cosmetics
SPEAKERS
Confirmed speakers to date include:
Sandy Aronson, Executive Director of IT, Partners HealthCare Center for Personalized Genetic Medicine (PCPGM)
Arindam Bhattacharjee, Ph.D., CEO and Founder, Parabase Genomics
Diana Bianchi, M.D., Executive Director, Mother Infant Research Institute; Vice Chair for Research, Department of Pediatrics, Floating Hospital for Children, Tufts Medical Center
Cinnamon Bloss, Ph.D., Assistant Professor and Director, Social Sciences and Bioethics, Scripps Translational Science Institute
Alexis Borisy, Partner, Third Rock Ventures
John Boyce, President and CEO, GnuBio
Mike Cariaso, Founder, SNPedia; Author of Promethease
Kenneth Chahine, Ph.D., J.D., Senior Vice President and General Manager, DNA, ancestry.com
Michael Christman, CEO, Coriell Institute for Medical Research
Cindy Crowninshield, RD, LDN, Licensed Registered Dietitian, Body Therapeutics & Sodexo; Founder, Eat2BeWell & Eat4YourGenes; Conference Director, Cambridge Healthtech Institute
Kevin Davies, Ph.D., Editor-in-Chief, Bio-IT World
Chris Dwan, Principal Investigator and Director, Professional Services, BioTeam
Jay Flatley, President & CEO, Illumina
Andrew C. Fish, Executive Director, AdvaMedDx
Dennis Gilbert, Ph.D., Founder, President and CEO, VitaPath Genetics
Rosalynn Gill, Ph.D., Vice President, Clinical Affairs, Boston Heart Diagnostics
Steve Gullans, Managing Director, Excel Venture Management
Don Hardison, President & CEO, Good Start Genetics, Inc.
Richard Kellner, Founder and President, Genome Health Solutions, Inc.
Robert Klein, Ph.D., Chief Business Development Officer, Complete Genomics
Isaac S. Kohane, M.D., Ph.D., Henderson Professor of Health Sciences and Technology, Children’s Hospital and Harvard Medical School; Director, Countway Library of Medicine; Director, i2b2 National Center for Biomedical Computing; Co-Director, HMS Center for Biomedical Informatics
Stan Lapidus, President, CEO and Founder, SynapDx
Gholson Lyon, M.D., Ph.D., Assistant Professor in Human Genetics, Cold Spring Harbor Laboratory; Research Scientist, Utah Foundation for Biomedical Research
Daniel MacArthur, Ph.D., Assistant Professor, Massachusetts General Hospital; Co-founder, Genomes Unzipped
Craig Martin, Chief Executive Officer, Feinstein Kean Healthcare
James McCullough, CEO and Founder, Exosome Diagnostics
Kevin McKernan, CSO, Courtagen Life Sciences
Neil A. Miller, Director of Informatics, Center for Pediatric Genomic Medicine, Children’s Mercy Hospital
Paul Morrison, Ph.D., Laboratory Director, Molecular Biology Core Facilities, Dana-Farber Cancer Institute
Geert-Jan Mulder, M.D., General Partner, Forbion Capital
Steve Murphy, M.D., Managing Partner, Wellspring Total Health
Michael Murray, M.D., Clinical Chief, Genetics Division, Brigham and Women’s Hospital; Instructor, Harvard Medical School, The Harvard Clinical and Translational Science Center
Brian T. Naughton, Ph.D., Founding Scientist, 23andMe
Nathan Pearson, Ph.D., Director of Research, Knome, Inc.
Michael S. Phillips, Ph.D., Canada Research Chair in Translational Pharmacogenomics; Director, Molecular Diagnostic Laboratory, Montreal Heart Institute; Associate Professor, Université de Montréal
John Quackenbush, Ph.D., Professor, Biostatistics and Computational Biology, Cancer Biology Center for Cancer Computational Biology, Dana-Farber Cancer Institute
Martin G. Reese, President and CEO, Omicia
Heidi L. Rehm, Ph.D., FACMG, Chief Laboratory Director, Molecular Medicine, Partners HealthCare Center for Personalized Genetic Medicine (PCPGM); Assistant Professor of Pathology, Harvard Medical School
Oliver Rinner, Ph.D., CEO, BiognoSYS AG
Meredith Salisbury, Senior Consultant, Bioscribe
Marc Salit, Group Leader, Biochemical Science and Multiplexed Biomolecular Science, National Institute of Standards and Technology
Lee Silver, Ph.D., Professor of Molecular Biology and Public Affairs; Faculty Associate, Science, Technology & Environmental Policy Program, Office of Population Research, and the Center for Health and Wellbeing, Woodrow Wilson School, Princeton University
Jamie Streator, Managing Director, Healthcare Investment Banking, Cowen & Company
Joseph V. Thakuria, M.D., MMSc, Attending Physician in Clinical and Biochemical Genetics Medical Genetics, Massachusetts General Hospital; Medical Director, Personal Genome Project; Harvard Catalyst Translational Genetics and Bioinformatics Program, MGH Center for Human Genetics Research
Samuil R. Umansky, M.D., Ph.D., D.Sc., Co-founder, CSO, and President, DiamiR LLC
David A. Weitz, Ph.D., Mallinckrodt Professor of Physics and Applied Physics, Harvard School of Engineering and Applied Sciences
Speaker to be Announced, Barclays
DAY 1: TECHNOLOGY
7:30 am Conference Registration
8:30 Opening Remarks
John Boyce, President and CEO, GnuBIO and Meredith Salisbury, Senior Consultant, Bioscribe
OPENING PLENARY SESSION
» 8:45 KEYNOTE PRESENTATION
Self-Discovery in the Age of Personal Genomes
Lee Silver, Ph.D., Professor of Molecular Biology and Public Affairs; Faculty Associate, Science, Technology & Environmental Policy Program, Office of Population Research, and the Center for Health and Wellbeing, Woodrow Wilson School, Princeton University
With blinding speed, the biomedical research enterprise is advancing the technology to read personal genomes with greater accuracy, in less time, and at less expense.Meanwhile, consumer genetics has blossomed from infancy to adolescence with an array of innovative consumer-facing products. This unanticipated cottage industry is struggling with growing pains in a mix of conflicted regulators, restless innovators, and demanding consumers. Genetic information, like all information, “wants to be free,” but the commercialization environment is not yet optimized for personal freedom.
9:40 The Era of Clinical Sequencing and Personalized Medicine
Michael Christman, CEO, Coriell Institute for Medical Research
Advances in understanding genomic variation and associated clinical phenotypes continue to increase while the cost of full genome sequencing rapidly declines. Having access to your genomic information will become increasingly important as physicians are progressively receptive to incorporating genomics into routine clinical practice. When you need a new prescription, it will be necessary for your physician to quickly and securely access your genetic data to understand drug efficacy prior to dosing. Who will patients and medical professionals trust to store and interpret the data? Coriell is positioned to significantly contribute to the research needed to accelerate the adoption and routine use of genomics in medicine.
10:20 FEATURED PRESENTATION
Stan Lapidus, President, CEO and Founder, SynapDx
10:50 Coffee Break
BIG DATA/ANALYSIS
11:20 IT Infrastructure Required to Manage Patient Genetic Test Results
Sandy Aronson, Executive Director of IT, Partners HealthCare Center for Personalized Genetic Medicine (PCPGM)
There are many challenges associated with getting the maximum value out of a genetic test. This talk will focus on information technology infrastructure that can help.
11:50 Issues in Genomics at Scale
Chris Dwan, Principal Investigator and Director, Professional Services, BioTeam
2012 marks, in many respects, the beginning of the second decade of high-throughput DNA sequencing. Robust, well understood solutions exist for many of the major technical challenges involved in operating a high-throughput genomics facility. Petabyte scale data storage, well suited to research computing in this space, provides a clean example. Certainly it still requires careful planning and thorough engineering to deploy such infrastructure. However, we can now purchase robust systems from multiple vendors rather than having to stitch together solutions in-house. Perhaps more importantly, we can rely on the experience of a community of peers who have been through the exercise before. By contrast, the legal, regulatory, ethical, and privacy concerns in this space have only begun to be explored. As we plan for the coming years, we must certainly plan for technical uncertainty. Technologists find themselves in the role of guessing at the future. As translational medicine, clinical genome sequencing, and other practices become the norm, we must assume extreme and occasionally capricious changes to the social ecosystem. This talk will explore these issues in the context of nearly a decade supporting research computing and genomics for a broad variety of institutions.
12:20 pm Sponsored Presentation (Opportunity Available)
12:50 Luncheon Presentation (Sponsorship Opportunity Available)
or Lunch on Your Own
MOLECULAR DIAGNOSTICS
2:05 Panel Discussion
Panelists will first give a brief presentation and then convene for a panel discussion.
Michael S. Phillips, Ph.D., Canada Research Chair in Translational Pharmacogenomics; Director, Molecular Diagnostic Laboratory, Montreal Heart Institute; Associate Professor, Université de Montréal (Moderator)
Molecular Diagnostics and the Patient/Consumer
Andrew C. Fish, Executive Director, AdvaMedDx
This presentation will envision a future in which molecular diagnostics are widely utilized not only for decision making by health professionals, but also for the development and use of a wide range of consumer products that include genetic tests themselves. The speaker will discuss various policy implications of this convergence of patient and consumer interests driven by the expanding availability of molecular diagnostics.
Bridging the Gap between Genetic Risk and Blood Diagnostics by Personalized Health Monitoring
Oliver Rinner, Ph.D., CEO, Biognosys AG
Biognosys has developed a solution to quantify and track protein levels over time from a drop of blood. With a novel mass spectrometric technology, we can record protein signals from 1000s of proteins in a single instrument run and store such digital protein maps in a digital bio-bank that can be screened in silico for known and novel biomarkers. We will provide this technology as personalized health monitoring to patients and consumers that seek actionable information about their state of health.
Measuring Disease Treatment and Progression at the Molecular Level without Biopsy
James McCullough, CEO and Founder, Exosome Diagnostics
Exosome has developed a solution that has the ability to measure, at the molecular level without biopsy, the dynamic nature of both treatment and disease progression. The company has developed a means of isolating exosomes: exosomes are shed into all biofluids, including blood, urine, and CSF, forming a stable source of intact, disease-specific nucleic acids. From these, the company is able to develop predictive gene expression profiles to achieve high sensitivity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. This technology obviates the need for biopsy, and provides a means for detection at a much earlier stage of treatment.
3:20 Refreshment Break
3:50 Sponsored Presentation (Opportunity Available)
SEQUENCING
4:20 Panel Discussion
Like a double helix, the future growth of consumer genetics is intimately entwined with technology advances in next-generation sequencing. While the industry excitedly awaits the commercial debut of potentially disruptive nanopore sequencing platforms, existing platforms continue to roll out new enhancements and sequencing strategies that bring us within striking distance of clinical-grade whole genome sequencing. This panel discussion brings together leaders from existing and emerging sequencing providers to present and debate a range of questions including the pros and cons of targeted versus whole-genome sequencing, the emergence of third-generation sequencing platforms, and the challenges of integrating genome sequencing into the clinic.
Paul Morrison, Ph.D., Laboratory Director, Molecular Biology Core Facilities, Dana-Farber Cancer Institute (Moderator)
Panelists:
John Boyce, President and CEO, GnuBIO
Robert Klein, Ph.D., Chief Business Development Officer, Complete Genomics Inc.
Speaker to be Announced, Life Technologies
Speaker to be Announced, Illumina
5:50-6:50 Welcome Reception in the Exhibit Hall with Poster Viewing
DAY 2: BUSINESS + TRANSLATION
7:45 am Morning Coffee
TRANSLATIONAL GENOMICS
8:15 Panel Discussion
Panelists will first give a brief presentation and then convene for a panel discussion.
Kevin Davies, Ph.D., Editor-in-Chief, Bio-IT World (Moderator)
All Genomes are Dysfunctional: The Challenges of Interpreting Whole-Genome Data from Healthy Individuals
Daniel MacArthur, Ph.D., Assistant in Genetics, Massachusetts General Hospital; Co-founder, Genomes Unzipped
Recent advances in DNA sequencing technology have made cheap, rapid interrogation of complete genome and exome sequences an almost mundane exercise, and have resulted in significant progress in the discovery of disease-causing sequence changes from the genomes of individuals with rare diseases or cancers. However, such successes do not necessarily translate into an improved ability to use genome-scale data to predict future disease probability for currently healthy individuals. In this presentation I will highlight some of the major technical and analytical challenges associated with developing predictive genomic medicine for the healthy majority.
Consumer Genomics: What do People do with Their Genomes?
Cinnamon Bloss, Ph.D., Assistant Professor and Director, Social Sciences and Bioethics, Scripps Translational Science Institute
Direct-to-consumer personalized genomic testing is controversial, and there are few empirical data to inform the debate regarding use and regulation. The Scripps Genomic Health Initiative is a large longitudinal cohort study of over 2,000 adults who have undergone testing with a commercially available genomic test. Findings from this initiative regarding the psychological, behavioral and clinical impacts of genomic testing on consumers will be presented.
Advances in Noninvasive Prenatal Genetic Testing: Does this Mean “Designer” Babies for All?
Diana Bianchi, M.D., Executive Director, Mother Infant Research Institute; Vice Chair for Research, Department of Pediatrics, Floating Hospital for Children, Tufts Medical Center
Noninvasive prenatal testing for Down syndrome and other chromosome disorders using massively parallel DNA sequencing techniques is now available on a clinical basis in the US. With expected advances in sequencing techniques it will soon be possible to take a blood sample from a pregnant woman and determine if her fetus has a chromosome abnormality or a single gene disorder. How much information do prospective couples want and how do these technical advances affect well-established algorithms for prenatal care?
Translating Genomics into Clinical Care
Heidi L. Rehm, Ph.D., FACMG, Chief Laboratory Director, Molecular Medicine, Partners HealthCare Center for Personalized Genetic Medicine (PCPGM); Assistant Professor of Pathology, Harvard Medical School
This talk will focus on approaches to integrate clinical sequencing into genomic medicine. It will cover next generation sequencing test development from disease panels to whole genomes and the interpretation and reporting of genetic variants identified in patients.
Impact of Genomic Sequencing on Public Health and Preventive Medicine
Joseph V. Thakuria, M.D., MMSc, Attending Physician in Clinical and Biochemical Genetics and Medical Director, Personal Genome Project, Massachusetts General Hospital Center for Human Genetics Research
Early findings in the Personal Genome Project (established by George Church) suggest significant impact for public health and preventive medicine. Solutions to accelerate clinical adoption and address large molecular data challenges will be explored.
9:30 FEATURED PRESENTATION
Genome-in-a-Bottle: Reference Materials and Methods for Confidence in Whole Genome Sequencing
Marc Salit, Group Leader, Biochemical Science and Multiplexed Biomolecular Science, National Institute of Standards and Technology
Genome-in-a-Bottle: Reference Materials and Methods for Confidence in Whole Genome Sequencing Clinical application of ultra high throughput sequencing (UHTS) or “Next Generation Sequencing” for hereditary genetic diseases and oncology is rapidly emerging. At present, there are no widely accepted genomic standards or quantitative performance metrics for confidence in variant calling. These are needed to achieve the confidence in measurement results expected for sound, reproducible research and regulated applications in the clinic. NIST has convened the “Genome-in-a-Bottle Consortium” to develop the reference materials, reference methods, and reference data needed to assess confidence in human whole genome variant calls. A principal motivation for this consortium is to develop an infrastructure of widely accepted reference materials and accompanying performance metrics to provide a strong scientific foundation for the development of regulations and professional standards for clinical sequencing.
10:00 Coffee Break in the Exhibit Hall with Poster Viewing
VENTURE CAPITAL & INVESTMENT BANKING
10:30 Panel Discussion
This “Funding to IPO Panel” consists of some of the top venture capitalists and investment bankers in therapeutics, diagnostics, and consumer genetics. This series of presentations and follow-on panel, will take attendees through the financial cycle – from funding to IPO, with VC’s and bankers highlighting the corporate criteria most important to them, and the metrics by which they make their decisions.
Panelists:
Geert-Jan Mulder, M.D., General Partner, Forbion Capital
Alexis Borisy, Partner, Third Rock Ventures
Steve Gullans, Managing Director, Excel Venture Management
Jamie Streator, Managing Director, Healthcare Investment Banking, Cowen & Company
Speaker to be Announced, Barclays
12:15 pm Luncheon Presentation (Sponsorship Opportunity Available)
or Lunch on Your Own
GENOME DATA: THE PHYSICIAN’S PERSPECTIVE
1:45 Panel Discussion
While making the effort to deploy genomics and sequence data in preventative and clinical care is a noble cause, it is also one that requires pragmatic solutions. This panel discussion will address practical issues related to the day-to-day use of genomic technologies in the clinic — from hospital to private practice to academia.
Steve Murphy, M.D., Managing Partner, Wellspring Total Health (Moderator)
Panelists:
Michael Murray, M.D., Clinical Chief, Genetics Division, Brigham and Women’s Hospital; Instructor, Harvard Medical School, The Harvard Clinical and Translational Science Center
Isaac Samuel Kohane, M.D., Ph.D., Henderson Professor of Health Sciences and Technology, Children’s Hospital and Harvard Medical School; Director, Countway Library of Medicine; Director, i2b2 National Center for Biomedical Computing; Co-Director, HMS Center for Biomedical Informatics
3:00 Refreshment Break in the Exhibit Hall with Poster Viewing
GENOME INTERPRETATION
3:30 Omicia: Interpreting Genomes for Clinical Relevance
Martin G. Reese, President and CEO, Omicia
Automatic annotation of variants and integration of disparate data sources is just the first step in the eventual adoption of genomes into clinical practice. The next step is reducing this complexity into the very few, actionable clinically relevant findings. We will show how we integrate such methods within an automated, comprehensive and easy-to-use platform for the interpretation of individual genome data. This system allows for prioritizing variants with respect to its potential clinical impact and is preloaded with clinical gene sets and proprietary annotations to enhance discovery and reporting of personal genes and variants. Furthermore, it is extensible and allows the integration of the user’s proprietary gene and variants sets. We will show several exome and genome analyses.
3:50 Personalized Genomic Interpretation with SNPedia and Promethease
Mike Cariaso, Founder, SNPedia; Author of Promethease
With whole genome prices falling and microarray genotyping accessible to ordinary people over the internet, the challenge is no longer in acquiring the raw data, but in interpreting and using it. In this talk, I will outline a freely available database of literature, organized by the relevant DNA position and phenotypic effects. A complementary analysis program reads raw genomic data and produces a hyperlinked and searchable report of known associations. It can also perform special processing of family trios (child, mother, father), make predictions about offspring, and identify shared ancestry.
4:10 GenoSpace: Creating an Information Ecosystem for 21st Century Genomic Medicine
John Quackenbush, Ph.D., Professor, Biostatistics and Computational Biology, Cancer Biology Center for Cancer Computational Biology, Dana-Farber Cancer Institute
New sequencing technologies are driving the cost of genomic data generation to unprecedented lows, making sequencing available as a potentially valuable clinical and diagnostic tool. The challenge is solving “the last 100 yards” problem–delivering the data to those who need to access it in a manner in which they can use it effectively. GenoSpace has developed technology to connect the diverse consumers and producers of genomic data, creating an ecosystem in which we have the potential to advance genomic medicine.
VISIONS FOR PERSONALIZED MEDICINE
» 4:30 KEYNOTE PRESENTATION
The Big Picture: Visions for Personalized Medicine
Jay Flatley, President and CEO, Illumina
5:30 Social Event and Party
DAY 3: APPLICATIONS
8:00 am Morning Coffee
» 8:30 KEYNOTE PRESENTATION
An Inside Look at How AncestryDNA Uses Population Genetics to Enrich Its Online Family History Experience
Kenneth Chahine, Ph.D., J.D., Senior Vice President & General Manager, DNA, ancestry.com
Ancestry.com is the world’s largest online resource for family history with an extensive collection of over 10 billion historical records that are digitized, indexed and made available online over the past 13 years. In May 2012, AncestryDNA launched a direct-to-consumer genealogical DNA test that delivers two results to customers. The first result predicts identity-by-descent and allows the customer to find genetic relatives within the AncestryDNA customer database. The second determines the customer’s admixture to provide a predicted genetic ethnicity using a state-of-the-art algorithm. The AncestryDNA team leverages pedigrees, documents, geographical information and its extensive biobank of worldwide DNA samples to conduct innovative research in population genetics and translates the complexities of genetic science into a simple, understandable, and meaningful user experience.
9:15 Past, Present and Future of Consumer Genetics, a Pioneer’s Perspective
Rosalynn Gill, Ph.D., Vice President, Clinical Affairs, Boston Heart Diagnostics
The first consumer genetics company, Sciona, founded by Rosaylnn Gill, launched its services in April 2001 in the UK in what was either a breakthrough in innovation or an act of incredible naiveté. Twelve years later, many lessons have been learned, but the jury is still out on the appropriate regulatory framework, the necessary industry standards and what constitutes a sustainable business model.
9:45 Sponsored Presentation (Opportunity Available)
10:15 Coffee Break in the Exhibit Hall with Poster Viewing
PRENATAL/NEONATAL DIAGNOSTICS
10:45 Panel Discussion
Panelists will first give a brief presentation and then convene for a panel discussion.
Meredith Salisbury, Senior Consultant, Bioscribe (Moderator)
Neonatal Genomic Medicine
Neil A. Miller, Director of Informatics, Center for Pediatric Genomic Medicine, Children’s Mercy Hospital
The causal gene is known for more than 3,500 monogenic diseases. Many of these can present in the neonatal period, causing up to 30% of neonatal intensive care unit admissions. In the last six months, we have started to offer very rapid diagnostic testing for these diseases at Children’s Mercy Hospital based on genome sequencing. The emerging indications and utility of neonatal genomic medicine will be discussed.
Screening Neonates by Targeted Next-Generation DNA Sequencing
Arindam Bhattacharjee, Ph.D., CEO and Founder, Parabase Genomics
We are developing a neonatal genome sequencing test that will allow screening and diagnosis of primarily newborns and infants affected with a disease or condition allowing prompt treatment. The current approach of DNA based genetic screening for symptomatic and high-risk is not focused around neonates, and so healthcare providers and parents are unable to understand the cause and treatment of the condition in absence of clear symptoms. Our test is unique in that it simultaneously screens and/or diagnoses hundreds of these conditions at once from a single sample, providing more comprehensive information to families and their physicians. It is yet affordable, and provides access to the high-resolution sequence data.
Using NGS Sequencing to Improve the Standard of Care for Routine Genetic Carrier Screening
Don Hardison, President & CEO, Good Start Genetics, Inc.
11:45 Luncheon Presentation (Sponsorship Opportunity Available)
or Lunch on Your Own
NUTRITION, FOOD GENETICS & COSMETICS
1:00 The Importance of Genetic Testing-Directed Vitamin Use
Dennis Gilbert, Ph.D., Founder, President and CEO, VitaPath Genetics
VitaPath Genetics, Inc. has developed a platform for genomic-based tests that determine the need for vitamin therapy in medically actionable conditions. Using its platform, VitaPath can develop specific vitamin-remediated risk assays that help manage the use of the $30 billion spent on supplements in the U.S. each year. The first test developed by VitaPath measures genetic risk factors associated with the spina bifida to identify women who would benefit from low-risk, prescription strength folic acid supplementation.
1:20 Using Weight Management Genetic Testing in Nutrition Counseling:
A Dietitian Weighs in on the Matter
Cindy Crowninshield, RD, LDN, Licensed Registered Dietitian, Body Therapeutics & Sodexo; Founder, Eat2BeWell & Eat4YourGenes; Conference Director, Cambridge Healthtech Institute
Between January-July 2012, 15 patients took a weight management genetic test to support their weight loss efforts. An individualized nutrition plan based on their eating and lifestyle habits and test results was created for each person. Data and several case studies will be presented to show how successful these patients were in achieving their weight loss goals. Challenges and opportunities will be discussed. Also presented will be tips and suggestions for genetic testing companies on how they can work best with a private practitioner’s office.
1:40 How Microfluidics is Changing the Landscape of Personalized Cosmetics
David A. Weitz, Ph.D., Mallinckrodt Professor of Physics and Applied Physics, Harvard School of Engineering and Applied Sciences
2:00 Refreshment Break in the Exhibit Hall with Poster Viewing
DISEASE DIAGNOSTICS
2:30 Clinical Sequencing and Mitochondrial Disease
Kevin McKernan, CSO, Courtagen Life Sciences
We describe the results from sequencing 64 patients’ Mitochondrial genomes in conjunction with 1,100 nuclear genes. Complementing this data with multiplex ELISA assays to monitor protein levels in the blood can provide additional insight to variants of unknown significance and aid therapeutic decisions.
2:50 A Paradigm Shift: Universal Screening Test
Samuil R. Umansky, M.D., Ph.D., D.Sc., Co-founder, CSO, and President, DiamiR LLC
We will present a fundamentally new approach to the development of a screening test aimed at diseases of various organ systems, organs and tissues. The test is non-invasive and cost efficient. The data we will present demonstrate the potential of our approach for early detection of neurodegenerative diseases, cancer and inflammatory diseases of gastrointestinal and pulmonary systems.
THE EMPOWERED PATIENT
3:10 Genomes R Us – How Personalized Medicine is Reshaping the Role of Patients, and Why It Matters
Craig Martin, CEO, Feinstein Kean Healthcare
Much has been said about the advancements in science underlying the genomic revolution. We are beginning now to see the impact at the clinical level, and there’s more to come in the pipeline. But what does this shift in medicine do to change the role of the patient? This presentation provides insights into how best to engage with patient communities to expedite research, commercialization and market impact of innovative technologies, diagnostics and treatments, and to help validate the relative efficacy of such advancements in a value-driven world.
3:40 Consumer Empowerment in Health Care and Personal Genomics: Ethical, Societal and Regulatory Considerations
Gholson Lyon, M.D., Ph.D., Assistant Professor in Human Genetics, Cold Spring Harbor Laboratory; Research Scientist, Utah Foundation for Biomedical Research
The pace of exome and genome sequencing is accelerating with the identification of many new disease-causing mutations in research settings, and it is likely that whole exome or genome sequencing could have a major impact in the clinical arena in the relatively near future. However, the human genomics community is currently facing several challenges, including phenotyping, sample collection, sequencing strategies, bioinformatics analysis, biological validation of variant function, clinical interpretation and validity of variant data, and delivery of genomic information to various constituents. I will review these challenges, with an eye toward consumer genetics.
4:10 It Hurts Less If You Know More: An Empowered Patient’s Diagnostic Odyssey
Richard Kellner, Co-Founder and President, Genome Health Solutions, Inc.
For the early detection, diagnosis and treatment of cancer, there is a wide gap between current “standards of care” and what is possible through the use of advanced genomic technologies. Over the past two years I learned this lesson first hand through personal experiences involving myself, close friends and family members. My story is one of serendipity, frustration and then hope. I learned that, unfortunately, where you live and who you know can greatly influence your quality of care. I also learned that you can overcome these limitations by becoming an “empowered patient” who actively seeks out doctors who are willing to get outside of their comfort zones and practice “participatory medicine,” sometimes at the cutting edge of new precision diagnostics. I will present a new roadmap that both patients and doctors can follow toward a new era of personalized genomic medicine.
COMPANIES THAT EMPOWER THE PATIENT
4:40 23andMe’s DTC Exome
Brian T. Naughton, Ph.D., Founding Scientist, 23andMe
In October 2011, 23andMe launched a $999 direct-to-consumer exome product to a limited group of customers.This talk presents findings from this project, including the ubiquitous issue of variants of unknown significance.
5:10 Winding the Asklepian Wand: The Advent of Whole Genomes in Healthcare
Nathan Pearson, Ph.D., Director of Research, Knome, Inc.
With ever cheaper sequencing, richer reference data, and sharper interpretation methods, the clinical use of whole genomes is taking root in pediatrics, oncology, and beyond. Our genomes will ultimately join other cornerstones of clinical care, helping us stay healthier from birth to old age. But that prospect will require fast, robust pipelines that smartly interpret genomes, in the context of good phenotype data, and feed decisive insights back to patients and caregivers. Learn how Knome is making that happen.
5:40 Close of Conference
Source:
http://www.consumergeneticsconference.com/cgc_content.aspx?id=117407&libID=117355
Like this:
Like Loading...
Read Full Post »